Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with Caucasian prostate cancer patients

被引:33
作者
Caruso, RP
Levinson, B
Melamed, J
Wieczorek, R
Taneja, S
Polsky, D
Chang, C
Zeleniuch-Jacquotte, A
Salnikow, K
Yee, H
Costa, M
Osman, I
机构
[1] NYU, Sch Med, Inst Canc, Kaplan Comprehens Canc Ctr,Dept Urol, New York, NY 10016 USA
[2] NYU, Inst Canc, Kaplan Comprehens Canc Ctr, Dept Environm Med, New York, NY USA
[3] NYU, Inst Canc, Kaplan Comprehens Canc Ctr, Dept Pathol, New York, NY USA
[4] NYU, Inst Canc, Kaplan Comprehens Canc Ctr, Dept Dermatol, New York, NY USA
关键词
D O I
10.1158/1078-0432.CCR-0604-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The protein encoded by N-myc downstream-regulated gene 1 (NDRG1) is a recently discovered protein whose transcription is induced by androgens and hypoxia. We hypothesized that NDRG1 expression patterns might reveal a biological basis for the disparity of clinical outcome of prostate cancer patients with different ethnic backgrounds. Experimental Design: Patients who underwent radical prostatectomy between 1990 and 2000 at Veterans Administration Medical Center of New York were examined. We studied 223 cases, including 157 African Americans and 66 Caucasians (T2, n = 144; greater than or equal toT3, n = 79; Gleason <7, n = 122; greater than or equal to7, n = 101). Three patterns of NDRG1 expression were identified in prostate cancer: (a) intense, predominately membranous staining similar to benign prostatic epithelium; (b) intense, nucleocytoplasmic localization; and (c) low or undetectable expression. We then examined the correlations between patients' clinicopathological parameters and different NDRG1 expression patterns. Results: In this study of patients with equal access to care, African-American ethnic origin was an independent predictor of prostate-specific antigen recurrence (P < 0.05). We also observed a significant correlation between different patterns of NDRG1 expression and ethnic origin. Pattern 2 was less frequent in African Americans (21% versus 38%), whereas the reverse was observed for pattern 3 (60% in African Americans versus 44% in Caucasians; P = 0.03). This association remained significant after controlling for both grade and stage simultaneously (P = 0.02). Conclusions: Our data suggest that different NDRG1 expression patterns reflect differences in the response of prostatic epithelium to hypoxia and androgens in African-American compared with Caucasian patients. Further studies are needed to determine the contribution of NDRG1 to the disparity in clinical outcome observed between the two groups.
引用
收藏
页码:222 / 227
页数:6
相关论文
共 31 条
[21]   Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: A multivariable analysis [J].
Powell, IJ ;
Dey, J ;
Dudley, A ;
Pontes, JE ;
Cher, ML ;
Sakr, N ;
Grignon, DJ ;
Wood, DP .
UROLOGY, 2002, 59 (06) :907-912
[22]   The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: A multivariate analysis of positive surgical margins [J].
Powell, IJ ;
Heilbrun, LK ;
Sakr, W ;
Grignon, D ;
Montie, J ;
Novallo, M ;
Smith, D ;
Pontes, JE .
UROLOGY, 1997, 49 (05) :726-731
[23]  
Salnikow K, 2000, CANCER RES, V60, P5630
[24]   The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia [J].
Salnikow, K ;
Kluz, T ;
Costa, M ;
Piquemal, D ;
Demidenko, ZN ;
Xie, KP ;
Blagosklonny, MV .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (06) :1734-1741
[25]  
Salnikow K, 2000, CANCER RES, V60, P38
[26]  
SORAHAN T, 1985, LANCET, V1, P459
[27]   Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system [J].
Tarman, GJ ;
Kane, CJ ;
Moul, JW ;
Thrasher, JB ;
Foley, JP ;
Wilhite, D ;
Riffenburgh, RH ;
Amling, CL .
UROLOGY, 2000, 56 (06) :1016-1020
[28]   The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells [J].
Ulrix, W ;
Swinnen, JV ;
Heyns, W ;
Verhoeven, G .
FEBS LETTERS, 1999, 455 (1-2) :23-26
[29]  
van Belzen N, 1998, HISTOL HISTOPATHOL, V13, P1233, DOI 10.14670/HH-13.1233
[30]  
VanBelzen N, 1995, EUR J BIOCHEM, V234, P843